FDA Approves All-Oral Venclexta-Calquence CLL Regimen with 35% Risk Reduction
The FDA approved the all-oral, fixed-duration combination of Venclexta and AstraZeneca’s Calquence for previously untreated chronic lymphocytic leukemia patients. AMPLIFY Phase 3 data showed 77% progression-free survival at three years versus 67% with chemoimmunotherapy, median PFS not reached versus 47.6 months, and a 35% lower risk of progression or death.
1. FDA Approval for First All-Oral Fixed-Duration Regimen
The U.S. regulatory agency approved the combined use of venetoclax and acalabrutinib as the first all-oral, fixed-duration treatment for previously untreated chronic lymphocytic leukemia. This represents a shift from indefinite therapies to a defined treatment course, potentially improving patient adherence and quality of life.
2. AMPLIFY Phase 3 Trial Outcomes
In the pivotal AMPLIFY trial, 77% of patients receiving the Venclexta-Calquence combination remained progression-free at three years, compared to 67% with standard chemoimmunotherapy. Median progression-free survival was not reached for the oral regimen versus 47.6 months for chemotherapy, and the dual therapy cut disease progression or death risk by 35%.
3. Market and Patient Impact
Chronic lymphocytic leukemia is one of the most prevalent adult leukemias, creating a substantial patient population for the new regimen. The oral, fixed-duration approach may drive faster adoption, support premium pricing, and bolster long-term revenue streams for AstraZeneca in the hematology segment.